AU2013202932A1 — Novel lipid formulations for nucleic acid delivery
Assigned to Protiva Biotherapeutics Inc · Expires 2013-05-02 · 13y expired
What this patent protects
H:\aar\Intenvoven\NRPortbl\DCC\AAR\5054850_ .DOC-8/04/2013 The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid part…
USPTO Abstract
H:\aar\Intenvoven\NRPortbl\DCC\AAR\5054850_ .DOC-8/04/2013 The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, ;and methods of delivering and/or administering the SNALP. 113b
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.